|
|
|
|
 |
SAN DIEGO--- Beverly A. Huss, CEO OF Vibrynt and Former Division President of Guidant Joins Artes Medical's Board of Directors |
| Companies mentioned in this article: |
|
Artes Medical - Guidant Corporation |
|
| 10/1/2007 @ 4:23 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced that Beverly A. Huss has joined its Board of Directors.
Ms. Huss has over 20 years of experience in medical device research and development, and is both an experienced operating executive in the medical device industry and public company director. Currently, Ms. Huss is the chief executive officer of Vibrynt, Inc., a venture-backed medical device company located in Mountain View, California. Prior to joining Vibrynt, Ms. Huss served as President, Endovascular Solutions and Vice President of Guidant Corporation, and led the formation of the business unit and the team that quadrupled worldwide revenues for the carotid and peripheral vascular business in four years. Ms. Huss also serves on the board of directors of Dade Behring, Inc. (Nasdaq:DADE), a public company in the medical device and diagnostic testing industry.
“With over 20 years of experience on the research, development and commercialization of medical devices, Beverly will further deepen and enrich our Board of Directors as we begin to accelerate the commercial phase and market launch of Artes Medical’s flagship product ArteFill, the first and only FDA-approved non-resorbable injectable dermal filler for the correction of facial wrinkles known as smile lines,” said Christopher J. Reinhard, Executive Chairman of Artes Medical.
Ms. Huss will fill the vacancy created by the recent resignation of Daren Barone. Mr. Barone served as a director since his election to the Board in 2004 when Artes Medical was a private company. With the achievement of FDA approval of Artes Medical’s flagship product ArteFill and the completion of the Company’s initial public offering, Mr. Barone is resigning from the Board to pursue other personal and professional interests.
“The Board and management deeply appreciates Daren’s wise counsel and many contributions during the Company’s transformation from a small private research and development start-up enterprise into a public company with fully-integrated cGMP manufacturing operations and a first-in-class FDA approved product during the past three years, and we wish him all the best in his many new and exciting private-company business ventures and investments,” said Mr. Reinhard.
About ArteFill®
ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres in ArteFill are not absorbed by the body and therefore provide the first-of-its-kind permanent support for long-lasting wrinkle correction in one to two treatments.
ArteFill was approved by the FDA in October 2006 based on data from the Company’s 12-month controlled, randomized, double-masked, multi-center U.S. clinical trial, which compared outcomes for patients treated with ArteFill with those of patients treated with the leading bovine collagen-based filler. At the 6-month evaluation, which was the primary efficacy evaluation period for the clinical trial, the wrinkle correction in patients treated with ArteFill persisted and showed statistically significant improvement compared to the wrinkle correction in the patients treated with the collagen control, who returned to their pretreatment status. The ArteFill patients were also evaluated one year after treatment, demonstrating continued safety and wrinkle correction.
In February 2007, the Company announced it completed a 5-year follow-up study of 145 patients who were treated with ArteFill in the Company's U.S. clinical trial. In addition to demonstrating the safety profile of ArteFill, the study showed statistically significant (p<0.001) improvement in patient wrinkle correction five years after the patient's last ArteFill treatment, and a statistically significant (p=0.002) improvement in wrinkle correction at the 5-year point compared to the 6-month evaluation period. As part of the study, physician investigators and patients were asked to provide their assessment of ArteFill treatment. Over 90% of the physician assessments were either "completely successful" or "very successful;" and over 90% of the patient assessments were either "very satisfied" or "satisfied." In March 2007, the Company submitted the data from the study to the FDA for review in order to enhance the product labeling for ArteFill.
An ArteFill Skin Test is required before initial treatment. The most common adverse events associated with ArteFill treatment, similar to those observed with other dermal fillers, are lumpiness, persistent swelling or redness and increased sensitivity at the injection site.
ArteFill is a proprietary formulation comprised of polymethylmethacrylate, or PMMA, microspheres and bovine collagen, and is the only PMMA-based injectable product that has been approved by the FDA for the treatment of facial wrinkles. Artes Medical is the sole manufacturer of ArteFill, which is only available in the United States directly from Artes Medical, and Artes Medical has not entered into distribution or licensing arrangements with any third party for the distribution or sale of ArteFill outside the United States.
About Artes Medical, Inc.
Artes Medical is a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for the dermatology and plastic surgery markets. The Company’s initial product, ArteFill, is being marketed to men and women as a treatment option for the correction of nasolabial folds. There were approximately two million dermal filler procedures in the U.S. in 2006, an increase of 25% over the prior year, according to the American Society for Aesthetic Plastic Surgery, or ASAPS. Additional information about Artes Medical and ArteFill is available at www.artesmedical.com and www.artefill.com. |
| Tech People On the Move - California |
|
|
| |
| Monday, October 6, 2008 |
 |
|
OXNARD--- CalAmp Appoints Mike Zachan Vice President and General Manager of Aercept Business Posted 7:02 AM PST
SAN DIEGO--- Bio-Quant Adds Dr. Roberto Crea to the Board Posted 6:51 AM PST
SAN DIEGO--- Biocept, Inc. Announces CEO and Director Appointments Posted 6:42 AM PST
|
| |
| Friday, October 3, 2008 |
|
|
IRVINE--- Marc Loupe Appointed CFO of Sage Software, Greg Hammermaster Appointed President of Payment Solutions Division Posted 6:26 AM PST
MURRIETA--- CLX Medical, Inc. Announces Appointment of CEO Vera Leonard to Board of Directors Posted 6:24 AM PST
|
| |
| Thursday, October 2, 2008 |
|
|
BELMONT--- Jameco Electronics Names Greg Harris Vice President of Marketing Posted 2:05 PM PST
FREMONT--- Virage Logic Announces Promotion of Dr. Alex Shubat to CEO, Chairman and Former CEO Dan McCranie Becomes Executive Chairman Posted 11:03 AM PST
SUNNYVALE--- Moonblink Communications Appoints VP of Business Development Posted 5:03 AM PST
|
| |
| Wednesday, October 1, 2008 |
|
|
SAN DIEGO--- GE Capital Solutions, Global Electronics Services Names Dan Hamling Director, IC Test and Assembly Posted 4:00 PM PST
SAN JOSE--- Symmetricom Announces Justin Spencer as New Chief Financial Officer Posted 3:58 PM PST
EL SEGUNDO--- Jay Schwartzberg Joins Accordent to Lead Eastern Region Sales Posted 3:50 PM PST
SAN FRANCISCO--- Stevana Case Joins fatfoogoo Executive Team Posted 9:53 AM PST
SANTA CLARA--- LiveOps Appoints PayPal Executive Ryan D. Downs to Board of Directors Posted 9:52 AM PST
SAN FRANCISCO--- ON24 Names Denise Persson as Chief Marketing Officer to Take Global Virtual Events Leadership to Next Level Posted 9:51 AM PST
MURRIETA--- CLX Medical, Inc. Announces Agreement for Kurt Kalm to Serve as Interim CFO Posted 7:37 AM PST
LOS ALTOS--- TravelMuse Appoints Russ Lemelin as Chief Financial Officer Posted 7:25 AM PST
LOS ANGELES--- iDcentrix Appoints New Technical Director Posted 7:04 AM PST
|
| |
| Monday, September 29, 2008 |
|
|
SAN JOSE--- Tessera Names Michael Anthofer as Executive Vice President and CFO New CFO Brings More Than 30 Years of Technology Company Financial Expertise Posted 8:32 AM PST
SAN FRANCISCO--- Linden Lab Appoints Tom Hale as Chief Product Officer Former Adobe Systems and Macromedia Executive to Join Senior Leadership Team of Linden Lab Posted 8:30 AM PST
|
| |
| Thursday, September 25, 2008 |
|
|
REDWOOD CITY--- PDL BioPharma Names Faheem Hasnain President and Chief Executive Officer Posted 3:54 PM PST
SAN DIEGO--- Anthony Arnerich Appointed Executive Chairman at Accumetrics Posted 3:36 PM PST
SAN DIEGO--- Orexigen Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders Posted 9:14 AM PST
|
| |
| Wednesday, September 24, 2008 |
|
|
SAN FRANCISCO--- Veteran Business Intelligence Professional Dyke Hensen Joins PivotLink as Chief Marketing Officer Posted 6:43 AM PST
SAN DIEGO--- Lpath Appoints John Bender, Pharm.D., as Senior Vice President of Research and Development Posted 6:42 AM PST
|
| |
| Tuesday, September 23, 2008 |
|
|
SAN JOSE--- IDT Names Richard D. Crowley, Jr. As Chief Financial Officer Posted 4:49 PM PST
MOUNTAIN VIEW--- Bytemobile Appoints Telecom Industry Veteran Nick Henry as Vice President, Worldwide Systems Integration Posted 8:53 AM PST
SAN DIEGO--- Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development Posted 8:48 AM PST
MOUNTAIN VIEW--- Technology Industry Veteran Fred Hessabi Joins BDNA Board of Directors Posted 8:42 AM PST
LOS ANGELES--- ImmunoCellular Therapeutics Elects Dr. James Bender to Position of Vice President, Clinical Development Posted 8:34 AM PST
SAN DIEGO--- Joshua Haims Joins Networkcar as Vice President of Finance Posted 7:57 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
